Pfizer Inc. (PFE)
Why Pfizer Investors Should Closely Monitor VAX-31
Investing in biotech and pharma stocks is certainly not for everyone, as these companies are vulnerable to various external risks. I turned bullish on Pfizer last January based on several reasons, including the expectations for a resumption in buybacks and the company's strategy shift to focus on profitable growth. A couple of days ago, Vaxcyte, a clinical-stage biotech company, reported promising results in a Phase 1/2 trial for its pneumococcal vaccine, threatening Prevnar, Pfizer's blockbuster drug.
Pfizer: Cheap For A Reason, But I Remain Bullish
Pfizer's stock is undervalued with a 48% upside potential, supported by robust product pipelines, strategic initiatives, and a high 5.94% forward dividend yield. Recent pipeline developments, including new cancer treatments and promising vaccine results, highlight Pfizer's commitment to innovation and strategic partnerships. Q2 results exceeded expectations, with revenues of $13.28 billion and an adjusted EPS of $0.60, leading to an increased FY2024 revenue guidance.
Pfizer (PFE) Ascends While Market Falls: Some Facts to Note
In the most recent trading session, Pfizer (PFE) closed at $28.39, indicating a +0.32% shift from the previous trading day.
Pfizer Inc. (PFE) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Pfizer Inc. (NYSE:PFE ) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 8:30 AM ET Company Participants David Denton - Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn All right, great. We're going to get started here.
3 Bargain-Priced Growth Stocks for Fall 2024
While market volatility may initially unsettle investors, it presents an opportunity to capitalize on discounted investment prospects. While the current bull market has favored some sectors, it hasn't been universally beneficial, leaving a trail of high-quality growth stocks facing significant price declines.
Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data.
At the highest dose tested, Vaxcyte's shot elicited a stronger immune response against 18 of the 20 strains compared with Pfizer's.
Pfizer and Valneva report positive results in mid-stage trial of Lyme disease vaccine
The Phase 2 trial was evaluating the vaccine called VLA15 following a second booster dose given one year after the first one.
Pfizer Stock: Graham P/E Shows Large Discounts
I view Pfizer Inc. as a leader in a defensive sector under temporary ROCE pressure. Its profit recovery and growth prospects are substantially underestimated by the prevailing market consensus. Even assuming the market's pessimistic consensus outlook, it is discounted by more than 10% from the Graham P/E.
Pfizer: Look Beyond COVID-19 And The Patent Cliffs - Robust Long-Term Tailwinds
PFE's bullish support has already been observed at the $25s, with the worst seemingly well behind us. Its core portfolio continues to generate robust growth at +14% YoY in FQ2'24 (excluding Comirnaty and Paxlovid), with Seagen's therapies already at $2.92B in annualized revenues. FY2025 is likely to bring forth an improved YoY comparison as well, with PFE's 3Y cost optimization program expected to boost their gross/ operating margins to pre-pandemic levels.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
2 Incredibly Cheap Growth Stocks to Buy Now
Stock market prices don't tell you everything, and that's certainly true with these businesses. Pfizer is paving the way to future growth, but investors might need to be patient.
Why Is Pfizer (PFE) Down 5.9% Since Last Earnings Report?
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?
